Tumor Biology

, Volume 37, Issue 12, pp 16207–16213 | Cite as

Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma

Original Article

Abstract

SAV1 is a human homolog of salvador that contains two protein-protein interaction modules known as WW domains and acts as a scaffolding protein for Hpo and Warts. SAV1 is known to be a tumor suppressor, but its clinical and prognostic implications remain elusive. This study aimed at evaluating the prognostic significance and associated expression of SAV1 in pancreatic ductal adenocarcinoma (PDAC) patients. The expression of SAV1 in tissue specimens of PDAC patients were assayed with immunohistochemistry on a tissue microarray. The correlations between SAV1 expression and clinicopathological characteristics were analyzed by Pearson’s chi-square test, Fisher’s exact test, and Spearman’s rank. The prognostic factors for overall survival were analyzed by univariate and multivariate Cox regression. The percentage of SAV1 expression in PDAC (50.6 %) was significantly lower than those in paratumor tissues (69.9 %) (P = 0.017). Expression of SAV1 was only significantly correlated with histological differentiation (P = 0.025) and N classification (P = 0.009). On multivariate analysis, elevated expression of SAV1 and N0 was a significant favorable prognostic factor of OS. Our study demonstrated for the first time that lower expression of SAV1 might be involved in the progression of PDAC, suggesting that SAV1 may be a potential prognostic marker and target for PDAC therapy.

Keywords

SAV1 Pancreatic ductal adenocarcinoma Prognosis Immunohistochemistry 

Notes

Acknowledgments

This work was supported by grant 81171887 and 91229117 from the National Natural Science Foundation of China (to L. Wang).

Compliance with ethical standards

The use of the tissue microarray was approved by the Medical ethics committee of the general hospital. And each patient included in the study has signed an informed consent form before the tissue was collected.

Conflicts of interest

None

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.CrossRefPubMedGoogle Scholar
  3. 3.
    Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Plouffe SW, Hong AW, Guan KL. Disease implications of the hippo/yap pathway. Trends Mol Med. 2015;21:212–22.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. The hippo pathway in biological control and cancer development. J Cell Physiol. 2011;226:928–39.CrossRefPubMedGoogle Scholar
  7. 7.
    Liu AM, Wong KF, Jiang X, Qiao Y, Luk JM. Regulators of mammalian hippo pathway in cancer. Biochim Biophys Acta. 2012;1826:357–64.PubMedGoogle Scholar
  8. 8.
    Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB. Group AS, Bowtell DD, Harvey KF: the hippo pathway transcriptional co-activator, yap, is an ovarian cancer oncogene. Oncogene. 2011;30:2810–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, Kishimoto H. The hippo pathway transcriptional co-activator, yap, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46:2364–70.PubMedGoogle Scholar
  10. 10.
    Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. The hippo-salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248–53.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    ZP X, Zhu JS, Zhang Q, Wang XY. A breakdown of the hippo pathway in gastric cancer. Hepato-Gastroenterology. 2011;58:1611–7.Google Scholar
  12. 12.
    Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M. Downregulation of sav1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer. 2011;11:523.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Machado-Neto JA, Lazarini M, Favaro P, Franchi Jr GC, Nowill AE, Saad ST, Traina F. Ankhd1, a novel component of the hippo signaling pathway, promotes yap1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014;324:137–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res. 2010;70:8517–25.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107:1437–42.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chen M, Wang M, Xu S, Guo X, Jiang J. Upregulation of mir-181c contributes to chemoresistance in pancreatic cancer by inactivating the hippo signaling pathway. Oncotarget. 2015;6:44466–79.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang L, Wei D, Huang S, Peng Z, Le X, TT W, Yao J, Ajani J, Xie K. Transcription factor sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMedGoogle Scholar
  18. 18.
    Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X, Ouyang X. Expression and prognosis value of shp2 in patients with pancreatic ductal adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:7853–9.CrossRefGoogle Scholar
  19. 19.
    Gao T, Zhou D, Yang C, Singh T, Penzo-Mendez A, Maddipati R, Tzatsos A, Bardeesy N, Avruch J, Stanger BZ. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology. 2013;144:1543–53 1553 e1541.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of yap. Mol Cell Biol. 2012;32:5116–28.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. Salvador promotes both cell cycle exit and apoptosis in drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–78.CrossRefPubMedGoogle Scholar
  22. 22.
    Varelas X. The hippo pathway effectors taz and yap in development, homeostasis and disease. Development. 2014;141:1614–26.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant kras, the transcription regulator yap is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7:ra42.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    MZ X, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer-. Am Cancer Soc. 2009;115:4576–85.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Lei Wang
    • 1
  • Yu Wang
    • 2
  • Peng-Ping Li
    • 3
  • Rui Wang
    • 1
  • Yue Zhu
    • 1
  • Fang Zheng
    • 1
  • Lin Li
    • 1
  • Jiu-Jie Cui
    • 2
  • Li-Wei Wang
    • 1
    • 2
  1. 1.Department of OncologyShanghai General Hospital of Nanjing Medical UniversityShanghaiChina
  2. 2.Department of Oncology and Shanghai Key Laboratory of Pancreatic DiseasesShanghai Jiaotong University Affiliated Shanghai First People’s HospitalShanghaiChina
  3. 3.Department of Bioinformatics, School of Basic Medical SciencesNanjing Medical University NanjingChina

Personalised recommendations